Cargando…

Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups

IMPORTANCE: Immune checkpoint inhibitors (ICIs) have improved survival outcomes of patients with advanced esophageal squamous cell carcinoma in both first- and second-line settings. However, the benefit of ICIs in patients with low programmed death ligand 1 (PD-L1) expression remains unclear. OBJECT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yap, Dominic Wei Ting, Leone, Alberto Giovanni, Wong, Nicky Zhun Hong, Zhao, Joseph J., Tey, Jeremy Chee Seong, Sundar, Raghav, Pietrantonio, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857522/ https://www.ncbi.nlm.nih.gov/pubmed/36480211 http://dx.doi.org/10.1001/jamaoncol.2022.5816

Ejemplares similares

Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score
por: Leone, A.G., et al.
Publicado: (2022)

KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves
por: Zhao, Joseph J., et al.
Publicado: (2022)

HaploBlocker: Creation of Subgroup-Specific Haplotype Blocks and Libraries
por: Pook, Torsten, et al.
Publicado: (2019)

Evolutionary Dynamics of Male Reproductive Genes in the Drosophila virilis Subgroup
por: Ahmed-Braimah, Yasir H., et al.
Publicado: (2017)

Checkpoint Regulation of Nuclear Tos4 Defines S Phase Arrest in Fission Yeast
por: Kim, Seong M., et al.
Publicado: (2019)

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022)

Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma
por: Zhu, Guanxia, et al.
Publicado: (2020)

Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
por: Jiao, Ruidi, et al.
Publicado: (2019)

Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition
por: Travis, Roman L., et al.
Publicado: (2020)

A prognostic nomogram that includes MPV in esophageal squamous cell carcinoma
por: He, Qiao, et al.
Publicado: (2023)

Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma
por: Shi, Zhenguo, et al.
Publicado: (2022)

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
por: Lamba, Nayan, et al.
Publicado: (2022)

Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling
por: Sudo, Kazuki, et al.
Publicado: (2019)

Development and Validation of Esophageal Squamous Cell Carcinoma Risk Prediction Models Based on an Endoscopic Screening Program
por: Han, Junming, et al.
Publicado: (2023)

Resistance to systemic immune checkpoint inhibition in the peritoneal niche
por: Chia, Daryl Kai Ann, et al.
Publicado: (2022)

The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma
por: van Laarhoven, Hanneke W.M., et al.
Publicado: (2023)

Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review
por: Zhang, Wencheng, et al.
Publicado: (2020)

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
por: Baba, Yoshifumi, et al.
Publicado: (2020)

Synthetic Physical Interactions Map Kinetochore-Checkpoint Activation Regions
por: Ólafsson, Guðjón, et al.
Publicado: (2016)

Assessment of the Diagnostic Performance of Endoscopic Ultrasonography After Conventional Endoscopy for the Evaluation of Esophageal Squamous Cell Carcinoma Invasion Depth
por: Ishihara, Ryu, et al.
Publicado: (2021)

Subgroups of Patients with Distinct Health Utility Profiles after AKI
por: Kwong, Yuenting D., et al.
Publicado: (2023)

Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials
por: Lu, Yao, et al.
Publicado: (2023)

Prevention of DNA Rereplication Through a Meiotic Recombination Checkpoint Response
por: Najor, Nicole A., et al.
Publicado: (2016)

Ubc1 turnover contributes to the spindle assembly checkpoint in Saccharomyces cerevisiae
por: Arsenault, Heather E, et al.
Publicado: (2021)

Association of Sialic Acid–Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy
por: Zhou, Sha, et al.
Publicado: (2023)

Effectiveness of S-1–Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial
por: Wang, Xin, et al.
Publicado: (2023)

Phylogenetic Reclassification of Vertebrate Melatonin Receptors To Include Mel1d
por: Denker, Elsa, et al.
Publicado: (2019)

Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
por: Sundar, Raghav, et al.
Publicado: (2020)

Global Gene Expression in Coprinopsis cinerea Meiotic Mutants Reflects Checkpoint Arrest
por: Anderson, Erika, et al.
Publicado: (2012)

Assessment of Intratumoral and Peritumoral Computed Tomography Radiomics for Predicting Pathological Complete Response to Neoadjuvant Chemoradiation in Patients With Esophageal Squamous Cell Carcinoma
por: Hu, Yihuai, et al.
Publicado: (2020)

Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial
por: Ai, Dashan, et al.
Publicado: (2022)

Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping
por: Jesinghaus, Moritz, et al.
Publicado: (2017)

The Yeast DNA Damage Checkpoint Kinase Rad53 Targets the Exoribonuclease, Xrn1
por: Lao, Jessica P., et al.
Publicado: (2018)

Rpd3L Contributes to the DNA Damage Sensitivity of Saccharomyces cerevisiae Checkpoint Mutants
por: Gómez-González, Belén, et al.
Publicado: (2019)

Checkpoint activation drives global gene expression changes in Drosophila nuclear lamina mutants
por: Kitzman, Samuel Cole, et al.
Publicado: (2021)

Long-term Incidence Rates of Esophageal Squamous Cell Carcinoma in Chinese Patients With Low-grade Intraepithelial Neoplasia and Association of Surveillance Endoscopy With Incidence
por: Li, He, et al.
Publicado: (2022)

Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
por: Wei, Tianhui, et al.
Publicado: (2022)

Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma
por: Zhao, Jing-Jing, et al.
Publicado: (2018)

Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy
por: Liao, Xiu-Yong, et al.
Publicado: (2019)

PD-L1 expression in medulloblastoma: an evaluation by subgroup
por: Martin, Allison M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_csod3r8h8e827ej2qndi4mukj8